Journal
JHEP REPORTS
Volume 3, Issue 6, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jhepr.2021.100346
Keywords
NAFLD; NASH; SREBP-1c; ChREBP; FXR; LXR; animal models; PPAR alpha; NEFA; glucotoxicity; lipotoxicity
Categories
Funding
- Agence Nationale de la Recherche [ANR-17-CE14-0015Hepadialogue]
- French association for the study of the liver (AFEF)
Ask authors/readers for more resources
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide with no effective treatments currently available. Preclinical models have enhanced our understanding of its pathophysiology, and research on new therapeutic targets is ongoing.
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets. (C) 2021 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
